Seoul National University Bundang Hospital (SNUBH)
| Corea del Sud | Turchia | Austria | |
| Chemioterapia per carcinoma mammario | da $19,200 | da $1,200 | da $15,000 |
| Radioterapia per il cancro colorettale | - | da $7,000 | da $12,000 |
Bookimed non aggiunge costi extra ai prezzi dei trattamenti di Cancro del fegato stadio 2. Le tariffe provengono dai listini ufficiali delle cliniche. Pagherai direttamente in clinica al tuo arrivo nel paese.
Bookimed si impegna per la tua sicurezza. Lavoriamo solo con strutture che mantengono elevati standard internazionali nei trattamenti di Cancro del fegato stadio 2 e hanno le licenze necessarie per servire pazienti internazionali in tutto il mondo.
Bookimed offre assistenza esperta gratuita. Un coordinatore medico personale ti supporta prima, durante e dopo il trattamento, risolvendo qualsiasi problema. Non sarai mai solo nel tuo percorso di trattamento per Cancro del fegato stadio 2.
Il dottore è un esperto in chirurgia oncoplastica e cancro al seno, con una vasta esperienza in istituzioni prestigiose. Il dottore possiede una laurea in medicina (M.D.) dal College of Medicine della Seoul National University e un master in chirurgia (M.S.) dalla stessa istituzione. Inoltre, il dottore ha conseguito una laurea in scienze biologiche (B.S.) presso il Korea Advanced Institute of Science and Technology (KAIST) e un dottorato di ricerca (Ph.D.) in chirurgia presso la Graduate School della Seoul National University.<\/p>
Liver transplantation is a common and safe curative option for stage 2 liver cancer in South Korea. Facilities like Asan Medical Center report 90% success rates for organ transplants. High-volume centers provide over 75% 5-year survival rates for eligible patients.
Bookimed Expert Insight: Patient volume is a reliable indicator of success in Korean transplant medicine. Asan Medical Center performs over 65,000 operations annually and handles 2,500+ inpatients daily. This massive volume helps surgeons maintain technical precision in complex living donor procedures. This expertise is a key reason why Korea reports some of the global highest survival rates.
Patient Consensus: Patients note that transplant is often a selective choice depending on cirrhosis and organ availability. They recommend confirming specific eligibility criteria at large tertiary centers before finalizing treatment plans.
South Korean centers utilize robotic liver resection and laparoscopic hepatectomy to treat stage 2 liver cancer. These techniques use small incisions to minimize trauma. Surgeons employ Indocyanine Green mapping for precision. This technology ensures negative margins while preserving healthy liver tissue and blood vessels.
Bookimed Expert Insight: Korea serves as a hub for extreme surgical volume. Seoul National University Hospital handles some of the highest cancer statistics nationally. This vast experience translates to high precision. Asan Medical Center performs over 65,000 operations annually. Such volume allows teams to master anatomical resections that are rare elsewhere.
Patient Consensus: Patients note that these specialized teams make a recovery feel much faster. They often emphasize that hospital stays are shorter than expected after laparoscopic procedures.
South Korea reports a 5-year survival rate of 71.3% for liver cancer patients. This significantly outperforms the global average and North American benchmarks of 50% to 70%. High surgical success and nationwide oncology surveillance contribute to these superior clinical outcomes in Korea.
Bookimed Expert Insight: While many countries maintain a 50% survival rate, top Korean clinics leverage massive patient volumes to refine expertise. Asan Medical Center alone handles over 65,000 operations annually. This high-repetition environment allows Korean surgeons to master complex techniques like robotic cancer surgery. Korea University Anam Hospital even developed the first robotic oral thyroid surgery method. For stage 2 liver cancer, this surgical precision is a critical factor in Korea's 71% survival advantage.
International patients in Korea access modern systemic therapies for stage 2 liver cancer including Atezolizumab-Bevacizumab combinations and targeted agents like Regorafenib or Sorafenib. JCI-accredited centers in Seoul provide these protocols for unresectable or recurrent cases following precise abdominal CT and chest CT diagnostics.
Bookimed Expert Insight: While many seek systemic drugs, Korean hospitals like Asan Medical Center and SNUH prioritize high-volume surgical expertise. Asan Medical Center performs over 65,000 operations annually with a 90% success rate in organ transplants. This surgical capacity often means patients initially diagnosed for systemic therapy may be re-evaluated for curative resection or advanced robotic surgery at centers like Korea University Anam Hospital.
Patient Consensus: Patients emphasize confirming tumor resectability before committing to drug-only plans. They note that bring exact pathology reports and PIVKA-II results is vital for a multidisciplinary review.
Routine follow-up for stage 2 liver cancer in Korea involves structured surveillance every 2 to 6 months during the first 2 years. Protocol-driven checks include dynamic contrast-enhanced CT scans, liver-specific MRI, and alpha-fetoprotein (AFP) blood tests to detect early recurrence.
Bookimed Expert Insight: Korean centers like Asan Medical Center and SNUH handle massive patient volumes, reaching millions annually. This scale creates highly efficient, digitalized follow-up systems where lab results and imaging are often reviewed on the same day. Patients benefit from this rapid turnaround as recurrence can be addressed immediately with local treatments or transplant-related evaluations.
Patient Consensus: Patients find the schedule more intensive than expected but value the fast turnaround for scans. Many note that appointments focus equally on managing underlying cirrhosis or hepatitis alongside cancer monitoring.